In patients without an actionable driver mutation, immune checkpoint inhibitors targeting the PD-1/PD-L1 immune checkpoints [5,6] have become the standard first line treatment for advanced non-small cell lung cancer (NSCLC) patients [7,8,9,10]. Here, CD274 is linked to non-small cell lung carcinoma.